Home | Structured Search | Drug Resource
Find: within
Sexual Assault > Drug Therapy Author: Carolyn J. Sachs, MD, MPH
Editorial changes - 2008-05-02
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up

Tables
Figures
References
Glossary
What's New
Patient Information
Additional Resources
Tools

Rationale:

  • Single-dose levonorgestrel, available as Plan B in the U.S., prevents 89% of pregnancies that would have otherwise occurred and causes fewer side effects than the other postcoital contraception regimens.

Evidence:

  • One review study concluded that as many as 22,000 rape-related pregnancies could be prevented yearly if all women who were raped received prompt medical services and, if not already protected against pregnancy, were provided with emergency contraceptive treatment (78).
  • A review of eight efficacy studies estimates that the combination of ethinyl estradiol and a progestin, known as the Yuzpe regimen, prevents approximately 74% of pregnancies that would have otherwise occurred (79).
  • One randomized large-scale prospective clinical trial of 1955 women showed that the progestin-only regimen, available as Plan B in the U.S., prevents significantly more than the Yuzpe regimen (80).
  • A randomized, double-blind trial in 15 family-planning clinics in 10 countries involving 4136 healthy women found that the progestin-only regimen (Plan B) may be given in a single dose of two pills with efficacy equal to the old two-dose plan (81).
  • A prospective observational study of 111 women showed that emergency contraception retains its usual efficacy up to 120 hours after coitus (81; 82).

Comments:

  • Plan B is currently FDA approved for postcoital contraception and is available without a prescription to persons aged 18 years and older. All available evidence proves no untoward effects on the fetus should pregnancy occur despite postcoital contraception. The common practice of obtaining written patient consent for these medications seems unwarranted.

FAQs
Carolyn J. Sachs, MD, MPH has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2008 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.